Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors
作者:Mingfeng Shao、Linhong He、Li Zheng、Lingxiao Huang、Yuanyuan Zhou、Taijing Wang、Yong Chen、Mingsheng Shen、Fang Wang、Zhuang Yang、Lijuan Chen
DOI:10.1016/j.bmcl.2017.07.054
日期:2017.9
compounds showed inhibitory activity against second bromdomains(BRD) of BRD4 and HDAC1. Among them, 16ae presented anti-proliferative effects against human acute myelogenous leukemia (AML) cell lines in vitro, and 16ae is confirmed to reduce the expression of Myc by Western blot analysis. Those results indicated that 16ae is a potent dual BRD4/HDAC inhibitor and deserves further investigation.
组蛋白乙酰化标记在控制基因表达中起重要作用,并被组蛋白脱乙酰基酶(HDAC)去除。这些标记由溴结构域和末端外(BET)蛋白读取,其靶向抑制剂正在临床研究中。BET和HDAC抑制剂已被证明在Myc诱导的鼠淋巴瘤中具有协同杀伤作用。在这里,我们通过基于结构的设计方法将BET和HDAC的抑制活性结合到一个分子中,并评估其功能。这些合成的化合物大多数显示出对BRD4和HDAC1的第二个bromdomains(BRD)的抑制活性。其中,16ae在体外对人急性骨髓性白血病(AML)细胞系具有抗增殖作用,并且Western印迹分析证实16ae可降低Myc的表达。